The Future of pMDIs: Plasma Technology
Sponsored by: Presspart
- Plasma Technology
Date: 22 June
Days to go: 39
Time: 2PM London
An innovative and sustainable pMDI surface treatment
With the introduction of new propellants and more complex formulations, the pMDI canister plays an increasingly significant role in the safe and efficacious delivery of drug to the patient. The relationship between propellant, drug and canister has significantly changed, with the canister no longer being just a safe containment system, but an integral part of the drug delivery itself.
There is also an ever increasing demand for sustainable drug delivery solutions, with pharmaceutical companies already committing to carbon free pMDI’s. H&T Presspart’s plasma surface treatment for MDI canisters, delivers advantages over existing technologies, providing a sustainable solution whilst improving all aspects of drug delivery performance.
During the webinar, participants will gain an understanding of the manufacturing process for H&T Presspart’s pMDI plasma cans and the sustainability benefits of this manufacturing process over other coated can processes such as anodised and FEP coated cans. Participants will also see how H&T Presspart’s inspection and quality process ensures the whole of the internal surface of the can treated with plasma.
Participants will also hear how Plasma can improve inhaler performance and combat drug degradation and drug adhesion, a common problem with many pMDIs. We will show attendees independent data comparing H&T Presspart’s plasma can performance versus other treatment processes as well as discussing which APIs are most suitable for Plasma.
Technical Application Engineer- MDDs
With a strong pharmaceutical and analytical background, Jacqueline is currently based at H&T Presspart’s Blackburn, UK site. She currently works within the Business Development team to provide technical expertise and support on every aspect of MDIs. Jacqueline is also responsible for the management of all Cannabis related projects across the globe. Jacqueline previously worked within H&T Presspart’s Inhalation Product Technology Centre, undertaking a wide range of in vitro analytical testing for MDI’s and formulations to support our customers product development.
Richard Turner has over 25 years’ experience in the pharmaceutical industry, with the last 20 years at H&T Presspart. Richard is currently responsible for H&T Presspart’s Global Sales Team, for the provision of components and devices for non-invasive drug delivery as well as services for the development of new drug delivery devices.
Key Learning Objectives
- Understand the plasma process and how plasma pMDI cans are manufactured
- How plasma pMDIs can improve inhaler performance
- H&T Pressparts testing and quality assurance processes for our plasma cans
- Sustainability benefits of plasma cans over other surface treatments
- Research & Development
- Supply chain
- Business Development
- Product Managers
- Managing Directors